A novel R848-conjugated inactivated influenza virus vaccine is efficacious and safe in a neonate nonhuman primate model

Journal of Immunology

Volumn 197, Issue 2, 2016, Pages 555-564

  Holbrook, Beth C ^a   Kim, Jong R ^a   Blevins, Lance K ^a   Jorgensen, Matthew J ^b   Kock, Nancy D ^b   D'Agostino, Ralph B ^b   Aycock, S Tyler ^b   Hadimani, Mallinath B ^c   King, S Bruce ^c   Parks, Griffith D ^a   Alexander Miller, Martha A ^a  

^a Room 2E 018 Wake Forest Bio Tech Place ^*  (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FLAGELLIN; RESIQUIMOD; TOLL LIKE RECEPTOR; VIRUS ANTIBODY; IMIDAZOLE DERIVATIVE; INACTIVATED VACCINE; INFLUENZA VACCINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CHLOROCEBUS AETHIOPS; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; INFANT; INFLUENZA; INFLUENZA A VIRUS (A/PUERTO RICO/8/1934(H1N1)); INFLUENZA VACCINATION; LUNG; NEWBORN; NONHUMAN; PRIORITY JOURNAL; VIRAL CLEARANCE; VIRUS LOAD; VIRUS NEUTRALIZATION; ANIMAL; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); METABOLISM; ORTHOMYXOVIRUS INFECTION;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FLAGELLIN; IMIDAZOLES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE INFECTIONS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; VACCINES, INACTIVATED;

EID: 84978058398     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600497     Document Type: Article

References (58)

1. Foote, E. M., R. J. Singleton, R. C. Holman, S. M. Seeman, C. A. Steiner, M. Bartholomew, and T. W. Hennessy. 2015. Lower respiratory tract infection hospitalizations among American Indian/Alaska Native children and the general United States child population. Int. J. Circumpolar Health 74: 29256.
2. Esposito, S., and N. Principi. 2009. The rational use of influenza vaccines in healthy children and children with underlying conditions. Curr. Opin. Infect. Dis. 22: 244-249.
3. Groothuis, J. R., M. J. Levin, G. P. Rabalais, G. Meiklejohn, and B. A. Lauer. 1991. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine. Pediatrics 87: 823-828.
4. Halasa, N. B., M. A. Gerber, Q. Chen, P. F. Wright, and K. M. Edwards. 2008. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. J. Infect. Dis. 197: 1448-1454.
5. Lin, J., S. Somanathan, S. Roy, R. Calcedo, and J. M. Wilson. 2010. Lung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenza. Vaccine 28: 5669-5675.
6. Tamura, S., T. Tanimoto, and T. Kurata. 2005. Mechanisms of broad crossprotection provided by influenza virus infection and their application to vaccines. Jpn. J. Infect. Dis. 58: 195-207.
7. Welliver, T. P., R. P. Garofalo, Y. Hosakote, K. H. Hintz, L. Avendano, K. Sanchez, L. Velozo, H. Jafri, S. Chavez-Bueno, P. L. Ogra, et al. 2007. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J. Infect. Dis. 195: 1126-1136.
8. Eichelberger, M. C., M. L. Wang, W. Allan, R. G. Webster, and P. C. Doherty. 1991. Influenza virus RNA in the lung and lymphoid tissue of immunologically intact and CD4-depleted mice. J. Gen. Virol. 72: 1695-1698.
9. Eichelberger, M., H. Golding, M. Hess, J. Weir, K. Subbarao, C. J. Luke, M. Friede, and D. Wood. 2008. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 26: 4299-4303.
10. Bungener, L., F. Geeraedts, W. Ter Veer, J. Medema, J. Wilschut, and A. Huckriede. 2008. Alum boosts TH2-type antibody responses to wholeinactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26: 2350-2359.
11. Moran, T. M., H. Park, A. Fernandez-Sesma, and J. L. Schulman. 1999. Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J. Infect. Dis. 180: 579-585.
12. Weldon, W. C., B. Z. Wang, M. P. Martin, D. G. Koutsonanos, I. Skountzou, and R. W. Compans. 2010. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One 5: e12466.
13. Siegrist, C. A. 2007. The challenges of vaccine responses in early life: selected examples. J. Comp. Pathol. 137(Suppl. 1): S4-S9.
14. Adkins, B., C. Leclerc, and S. Marshall-Clarke. 2004. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4: 553-564.
15. Zaghouani, H., C. M. Hoeman, and B. Adkins. 2009. Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. Trends Immunol. 30: 585-591.
16. Li, L., H. H. Lee, J. J. Bell, R. K. Gregg, J. S. Ellis, A. Gessner, and H. Zaghouani. 2004. IL-4 utilizes an alternative receptor to drive apoptosis of Th1 cells and skews neonatal immunity toward Th2. Immunity 20: 429-440.
17. Lee, H. H., C. M. Hoeman, J. C. Hardaway, F. B. Guloglu, J. S. Ellis, R. Jain, R. Divekar, D. M. Tartar, C. L. Haymaker, and H. Zaghouani. 2008. Delayed maturation of an IL-12-producing dendritic cell subset explains the early Th2 bias in neonatal immunity. J. Exp. Med. 205: 2269-2280.
18. Roux, X., A. Remot, A. Petit-Camurdan, M. A. Nahori, H. Kiefer-Biasizzo, G. Marchal, M. Lagranderie, and S. Riffault. 2011. Neonatal lung immune responses show a shift of cytokines and transcription factors toward Th2 and a deficit in conventional and plasmacytoid dendritic cells. Eur. J. Immunol. 41: 2852-2861.
19. Naderi, N., A. A. Pourfathollah, K. Alimoghaddam, and S. M. Moazzeni. 2009. Cord blood dendritic cells prevent the differentiation of na?ve T-helper cells towards Th1 irrespective of their subtype. Clin. Exp. Med. 9: 29-36.
20. Winkler, S., M. Willheim, K. Baier, D. Schmid, A. Aichelburg, W. Graninger, and P. G. Kremsner. 1999. Frequency of cytokine-producing T cells in patients of different age groups with Plasmodium falciparum malaria. J. Infect. Dis. 179: 209-216.
21. Xainli, J., M. Baisor, W. Kastens, M. Bockarie, J. H. Adams, and C. L. King. 2002. Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans. J. Immunol. 169: 3200-3207.
22. Randolph, D. A. 2005. The neonatal adaptive immune system. Neoreviews 6: e454-e462.
23. Zhao, Y., Z. P. Dai, P. Lv, and X. M. Gao. 2002. Phenotypic and functional analysis of human T lymphocytes in early second-and third-trimester fetuses. Clin. Exp. Immunol. 129: 302-308.
24. Clerici, M., L. DePalma, E. Roilides, R. Baker, and G. M. Shearer. 1993. Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages. J. Clin. Invest. 91: 2829-2836.
25. Miscia, S., A. Di Baldassarre, G. Sabatino, E. Bonvini, R. A. Rana, M. Vitale, V. Di Valerio, and F. A. Manzoli. 1999. Inefficient phospholipase C activation and reduced Lck expression characterize the signaling defect of umbilical cord T lymphocytes. J. Immunol. 163: 2416-2424.
26. + T cell responses to herpes simplex virus type 2 in neonatal mice. J. Immunol. 180: 1556-1564.
27. Holbrook, B. C., S. L. Hayward, L. K. Blevins, N. Kock, T. Aycock, G. D. Parks, and M. A. Alexander-Miller. 2015. Nonhuman primate infants have an impaired respiratory but not systemic IgG antibody response following influenza virus infection. Virology 476: 124-133.
28. Maisonneuve, C., S. Bertholet, D. J. Philpott, and E. De Gregorio. 2014. Unleashing the potential of NOD-and Toll-like agonists as vaccine adjuvants. Proc. Natl. Acad. Sci. USA 111: 12294-12299.
29. Fujita, Y., and H. Taguchi. 2012. Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines. Ther. Deliv. 3: 749-760.
30. Ma, R., J. L. Du, J. Huang, and C. Y. Wu. 2007. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem. Biophys. Res. Commun. 361: 537-542.
31. Wille-Reece, U., B. J. Flynn, K. Loré, R. A. Koup, R. M. Kedl, J. J. Mattapallil, W. R. Weiss, M. Roederer, and R. A. Seder. 2005. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl. Acad. Sci. USA 102: 15190-15194.
32. Tomai, M. A., R. L. Miller, K. E. Lipson, W. C. Kieper, I. E. Zarraga, and J. P. Vasilakos. 2007. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev. Vaccines 6: 835-847.
33. Vasilakos, J. P., and M. A. Tomai. 2013. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev. Vaccines 12: 809-819.
34. Levy, O., E. E. Suter, R. L. Miller, and M. R. Wessels. 2006. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 108: 1284-1290.
35. + regulatory T cell function. Science 309: 1380-1384.
36. Warger, T., P. Osterloh, G. Rechtsteiner, M. Fassbender, V. Heib, B. Schmid, E. Schmitt, H. Schild, and M. P. Radsak. 2006. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108: 544-550.
37. Krumbiegel, D., F. Zepp, and C. U. Meyer. 2007. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells. Hum. Immunol. 68: 813-822.
38. Klimov, A., A. Balish, V. Veguilla, H. Sun, J. Schiffer, X. Lu, J. M. Katz, and K. Hancock. 2012. Influenza virus titration, antigenic characterization, and serological methods for antibody detection. Methods Mol. Biol. 865: 25-51.
39. McDermott, P. F., F. Ciacci-Woolwine, J. A. Snipes, and S. B. Mizel. 2000. High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation. Infect. Immun. 68: 5525-5529.
40. Weimer, E. T., S. E. Ervin, D. J. Wozniak, and S. B. Mizel. 2009. Immunization of young African green monkeys with OprF epitope 8-OprI-type A-and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine 27: 6762-6769.
41. Honko, A. N., and S. B. Mizel. 2004. Mucosal administration of flagellin induces innate immunity in the mouse lung. Infect. Immun. 72: 6676-6679.
42. Manicassamy, B., S. Manicassamy, A. Belicha-Villanueva, G. Pisanelli, B. Pulendran, and A. Garc?a-Sastre. 2010. Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc. Natl. Acad. Sci. USA 107: 11531-11536.
43. Kim, J. R., B. C. Holbrook, S. L. Hayward, L. K. Blevins, M. J. Jorgensen, N. D. Kock, K. De Paris, R. B. D'Agostino, Jr., S. T. Aycock, S. B. Mizel, et al. 2015. Inclusion of flagellin during vaccination against influenza enhances recall responses in nonhuman primate neonates. J. Virol. 89: 7291-7303.
44. Ketloy, C., A. Engering, U. Srichairatanakul, A. Limsalakpetch, K. Yongvanitchit, S. Pichyangkul, and K. Ruxrungtham. 2008. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Vet. Immunol. Immunopathol. 125: 18-30.
45. Turley, C. B., R. E. Rupp, C. Johnson, D. N. Taylor, J. Wolfson, L. Tussey, U. Kavita, L. Stanberry, and A. Shaw. 2011. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29: 5145-5152.
46. Taylor, D. N., J. J. Treanor, C. Strout, C. Johnson, T. Fitzgerald, U. Kavita, K. Ozer, L. Tussey, and A. Shaw. 2011. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 29: 4897-4902.
47. + T cells. J. Immunol. 175: 1551-1557.
48. Bekeredjian-Ding, I. B., M. Wagner, V. Hornung, T. Giese, M. Schnurr, S. Endres, and G. Hartmann. 2005. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174: 4043-4050.
49. Bourke, E., D. Bosisio, J. Golay, N. Polentarutti, and A. Mantovani. 2003. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102: 956-963.
50. Kabelitz, D. 2007. Expression and function of Toll-like receptors in T lymphocytes. Curr. Opin. Immunol. 19: 39-45.
51. Wang, G., Y. Miyahara, Z. Guo, M. Khattar, S. M. Stepkowski, and W. Chen. 2010. Default generation of neonatal regulatory T cells. J. Immunol. 185: 71-78.
52. De Wit, D., S. Tonon, V. Olislagers, S. Goriely, M. Boutriaux, M. Goldman, and F. Willems. 2003. Impaired responses to toll-like receptor 4 and toll-like receptor 3 ligands in human cord blood. J. Autoimmun. 21: 277-281.
53. Levy, O., M. Coughlin, B. N. Cronstein, R. M. Roy, A. Desai, and M. R. Wessels. 2006. The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J. Immunol. 177: 1956-1966.
54. Kollmann, T. R., J. Crabtree, A. Rein-Weston, D. Blimkie, F. Thommai, X. Y. Wang, P. M. Lavoie, J. Furlong, E. S. Fortuno, III, A. M. Hajjar, et al. 2009. Neonatal innate TLR-mediated responses are distinct from those of adults. J. Immunol. 183: 7150-7160.
55. Lynn, G. M., R. Laga, P. A. Darrah, A. S. Ishizuka, A. J. Balaci, A. E. Dulcey, M. Pechar, R. Pola, M. Y. Gerner, A. Yamamoto, et al. 2015. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat. Biotechnol. 33: 1201-1210.
56. Trinchieri, G., and A. Sher. 2007. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7: 179-190.
57. Zhu, Q., C. Egelston, S. Gagnon, Y. Sui, I. M. Belyakov, D. M. Klinman, and J. A. Berzofsky. 2010. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J. Clin. Invest. 120: 607-616.
58. McCarron, M., and D. J. Reen. 2009. Activated human neonatal CD8+ T cells are subject to immunomodulation by direct TLR2 or TLR5 stimulation. J. Immunol. 182: 55-62.